Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Kavalerchik · SciRah

Researcher profile · Semantic Scholar

E. Kavalerchik

Share profile

E. Kavalerchik — researcher profile on SciRah

h-index: 5
Works: 20
Citations: 429

Most-cited papers

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
I. Geron, Annelie Abrahamsson, C. Barroga, E. Kavalerchik +9 more
2008Cancer Cell148 citations Open access
Semantic Scholar
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Michael L. Wang, T. Martin, W. Bensinger, M. Alsina +5 more
2013Blood134 citations Open access
Semantic Scholar
Chronic myeloid leukemia stem cells.
E. Kavalerchik, D. Goff, C. Jamieson
2008Journal of Clinical Oncology79 citations
Semantic Scholar
Investigation of the ATP binding site of Escherichia coli aminoimidazole ribonucleotide synthetase using affinity labeling and site-directed mutagenesis.
E. Mueller, S. Oh, E. Kavalerchik, T. J. Kappock +4 more
1999Biochemistry23 citations
Semantic Scholar
Abstract P1-16-05: MDV3100-08: A phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer
A. Elias, H. Burris, Patel, L. Schwartzberg +7 more
20166 citations
Semantic Scholar
436PDPreliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors
R. Aggarwal, A. Mansfield, H. Beltran, A. Farago +16 more
20175 citations Open access
Semantic Scholar
Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma.
Michael L. Wang, T. Martin, W. Bensinger, M. Alsina +3 more
20135 citations
Semantic Scholar
Inhibition of Chronic Myelogenous Leukemia Stem Cells with Novel Wnt Antagonists.
E. Kavalerchik, J. Gotlib, I. Geron, Annelie Abrahamsson +8 more
20065 citations
Semantic Scholar
Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)
M. Scordo, L. Budde, M. Abedi, C. Mulroney +8 more
2020Blood4 citations Open access
Semantic Scholar
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma
R. Vij, Michael L. Wang, S. Jagannath, R. Niesvizky +4 more
2015Leukemia and Lymphoma4 citations
Semantic Scholar
Missplicing of Glycogen Synthase Kinase 3β: A Potential Mechanism of Blast Crisis Chronic Myeloid Leukemia Stem Cell Generation.
Annelie Abrahamsson, I. Geron, J. Gotlib, Kim-Hien T. Dao +12 more
20074 citations
Semantic Scholar
Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.
I. Geron, C. Barroga, J. Gotlib, E. Kavalerchik +10 more
20064 citations
Semantic Scholar
An open-label study of rovalpituzumab tesirine in patients with DLL3-expressing advanced solid tumors.
E. Kavalerchik, S. Lally, T. Han, L. Saunders +2 more
20173 citations
Semantic Scholar
Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC).
V. Koshkin, P. Elson, C. Magi-Galluzzi, Jesse K. McKenney +15 more
20173 citations
Semantic Scholar
Aberrant Regulation of Wnt/Beta-Catenin Pathway Mediators in Chronic Myelogenous Leukemia Stem Cells.
Annelie Abrahamsson, I. Geron, J. Gotlib, J. Durocher +8 more
20062 citations
Semantic Scholar
Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors (DOI: 10.1016/j.ccr.2008.02.017)
I. Geron, Annelie Abrahamsson, C. Barroga, E. Kavalerchik +9 more
20081 citations Open access
Semantic Scholar
Severe GI Toxicities Remain a Significant Source of Clinical Meaningful Morbidity Especially in Older Patients Receiving Autologous Transplant for Lymphoma
G. Shouse, A. K. Frank, S. Aggarwal, E. Kavalerchik +3 more
2021Blood0 citations Open access
Semantic Scholar
Results of an Open Label Dose Escalation Trial of AB-205 (E-CEL® cells) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)
L. Budde, M. Scordo, M. Abedi, C. Mulroney +9 more
20210 citations Open access
Semantic Scholar
Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma
R. Vij, Michael L. Wang, S. Jagannath, R. Niesvizky +4 more
20130 citations
Semantic Scholar
A Novel Mouse Xenograft Model for Generation of JAK2 V617F Driven Leukemic Stem Cells From Human Embryonic Stem Cells.
E. Kavalerchik, C. Barroga, L. Balaian, J. Black +1 more
20090 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Jamieson×8
Invite
C. Jamieson — researcher profile on SciRah
I. Geron×6
Invite
I. Geron — researcher profile on SciRah
Annelie Abrahamsson×6
Invite
Annelie Abrahamsson — researcher profile on SciRah
J. Gotlib×6
Invite
J. Gotlib — researcher profile on SciRah

×4

Invite

C. Barroga — researcher profile on SciRah

Invite

J. Durocher — researcher profile on SciRah

Michael L. Wang×4

Invite

Michael L. Wang — researcher profile on SciRah

Invite

D. Siegel — researcher profile on SciRah

R. Niesvizky×4

Invite

R. Niesvizky — researcher profile on SciRah

Invite

D. Goff — researcher profile on SciRah

Invite

I. Weissman — researcher profile on SciRah

Invite

J. Hood — researcher profile on SciRah